Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Genevieve Marie Boland, Ph.D., M.D.

Title
Institution
Department
Address
Phone

Overview

Featured Content

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Miller PG, Gibson CJ, Mehta A, Sperling AS, Frederick DT, Manos MP, Miao B, Hacohen N, Hodi FS, Boland GM, Ebert BL. Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade. JCO Precis Oncol. 2020; 4. PMID: 33015529.
    Citations:    
  2. Drokhlyansky E, Smillie CS, Van Wittenberghe N, Ericsson M, Griffin GK, Eraslan G, Dionne D, Cuoco MS, Goder-Reiser MN, Sharova T, Kuksenko O, Aguirre AJ, Boland GM, Graham D, Rozenblatt-Rosen O, Xavier RJ, Regev A. The Human and Mouse Enteric Nervous System at Single-Cell Resolution. Cell. 2020 Sep 17; 182(6):1606-1622.e23. PMID: 32888429.
    Citations:    Fields:    
  3. Marusak C, Thakur V, Li Y, Freitas JT, Zmina PM, Thakur VS, Chang M, Gao M, Tan J, Xiao M, Lu Y, Mills GB, Flaherty K, Frederick DT, Miao B, Sullivan RJ, Moll T, Boland GM, Herlyn M, Zhang G, Bedogni B. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. Clin Cancer Res. 2020 Aug 20. PMID: 32820016.
    Citations:    Fields:    
  4. Lareau CA, Ludwig LS, Muus C, Gohil SH, Zhao T, Chiang Z, Pelka K, Verboon JM, Luo W, Christian E, Rosebrock D, Getz G, Boland GM, Chen F, Buenrostro JD, Hacohen N, Wu CJ, Aryee MJ, Regev A, Sankaran VG. Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. Nat Biotechnol. 2020 Aug 12. PMID: 32788668.
    Citations:    Fields:    
  5. Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, van Akkooi ACJ, Flaherty KT, Boland GM, Peeper DS. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nat Commun. 2020 08 07; 11(1):3946. PMID: 32770055.
    Citations:    Fields:    Translation:HumansAnimalsCells
  6. Guhan S, Boland G, Tanabe K, Lin W, Reddy B, Hawryluk EB, Sober AJ, Tsao H. Surgical Delay and Mortality for Primary Cutaneous Melanoma. J Am Acad Dermatol. 2020 Jul 22. PMID: 32711092.
    Citations:    Fields:    
  7. Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, Bowling P, Hodi FS, Rahma O, Sullivan RJ, Boland GM, Nowak JA, Dougan SK, Dougan M, Yuan GC, Wucherpfennig KW. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell. 2020 Aug 06; 182(3):655-671.e22. PMID: 32603654.
    Citations: 1     Fields:    
  8. Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, Maloney D, Patel K, Liao W, Widman AJ, Wong P, Callahan MK, Ha G, Reed S, Rotem D, Frederick D, Sharova T, Miao B, Kim T, Gydush G, Rhoades J, Huang KY, Omans ND, Bolan PO, Lipsky AH, Ang C, Malbari M, Spinelli CF, Kazancioglu S, Runnels AM, Fennessey S, Stolte C, Gaiti F, Inghirami GG, Adalsteinsson V, Houck-Loomis B, Ishii J, Wolchok JD, Boland G, Robine N, Altorki NK, Landau DA. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020 07; 26(7):1114-1124. PMID: 32483360.
    Citations:    Fields:    Translation:Humans
  9. Rauwerdink DJW, Molina G, Frederick DT, Sharova T, van der Hage J, Cohen S, Boland GM. Mixed Response to Immunotherapy in Patients with Metastatic Melanoma. Ann Surg Oncol. 2020 Sep; 27(9):3488-3497. PMID: 32472413.
    Citations:    Fields:    
  10. Rauwerdink DJW, Boland GM. ASO Author Reflections: Adjuvant Treatment of Melanoma in the Modern Era. Ann Surg Oncol. 2020 May 28. PMID: 32468350.
    Citations:    Fields:    
  11. Rauwerdink DJW, Boland GM. ASO Author Reflections: Mixed Response in Metastatic Melanoma Patients Treated with Immunotherapy. Ann Surg Oncol. 2020 Sep; 27(9):3498-3499. PMID: 32458325.
    Citations:    Fields:    
  12. Rauwerdink DJW, Molina G, Frederick DT, Sharova T, Carmichael H, Boland GM. Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management. Ann Surg Oncol. 2020 May 23. PMID: 32447656.
    Citations:    Fields:    
  13. Li Z, Wang B, Gu S, Jiang P, Sahu A, Chen CH, Han T, Shi S, Wang X, Traugh N, Liu H, Liu Y, Wu Q, Brown M, Xiao T, Boland GM, Shirley Liu X. CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma. Genomics Proteomics Bioinformatics. 2020 02; 18(1):26-40. PMID: 32413516.
    Citations:    Fields:    
  14. Sharma S, Zhang T, Michowski W, Rebecca VW, Xiao M, Ferretti R, Suski JM, Bronson RT, Paulo JA, Frederick D, Fassl A, Boland GM, Geng Y, Lees JA, Medema RH, Herlyn M, Gygi SP, Sicinski P. Targeting the cyclin-dependent kinase 5 in metastatic melanoma. Proc Natl Acad Sci U S A. 2020 04 07; 117(14):8001-8012. PMID: 32193336.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  15. Molina G, Kasumova GG, Qadan M, Boland GM. Use of immunotherapy and surgery for stage IV melanoma. Cancer. 2020 Jun 01; 126(11):2614-2624. PMID: 32157676.
    Citations:    Fields:    
  16. Rao PK, Barker C, Coit DG, Joseph RW, Materin M, Rengan R, Sosman J, Thompson JA, Albertini MR, Boland G, Carson Iii WE, Contreras C, Daniels GA, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossman K, Guild V, Johnson D, Karakousis G, Lange JR, Margolin K, Nath S, Olszanski AJ, Ott PA, Ross MI, Salama AK, Skitzki J, Swetter SM, Wuthrick E, McMillian NR, Engh A. NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. J Natl Compr Canc Netw. 2020 02; 18(2):120-131. PMID: 32023525.
    Citations:    Fields:    
  17. Parikh A, Van Seventer E, Boland G, Hartwig A, Jaimovich A, Raymond V, Talasaz A, Corcoran R. Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer. Ann Oncol. 2019 Jul; 30 Suppl 4:iv131. PMID: 32085033.
    Citations:    
  18. Nassour I, Balentine C, Boland GM, Chu D, Habermann E, Holscher C, Idrees K, In H, Kimbrough MK, Mitchem J, Warner SG, Karakousis G. Successful Mentor-Mentee Relationship. J Surg Res. 2020 03; 247:332-334. PMID: 31733816.
    Citations:    Fields:    Translation:Humans
  19. Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hammond SA, Tan M, Qi J, Wong P, Merghoub T, Wolchok J, Hacohen N, Janik JE, Mkrtichyan M, Gupta S, Khleif SN. Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 Nov; 20(11):1555. PMID: 31551574.
    Citations: 1     Fields:    
  20. Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flückiger-Mangual S, Vukolic A, Eichhoff O, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, Wei Z, Sullivan RJ, Boland GM, Herlyn M, Flaherty KT, Zamboni N, Dummer R, Zhang G, Levesque MP, Krek W, Kovacs WJ. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clin Cancer Res. 2019 11 15; 25(22):6852-6867. PMID: 31375515.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  21. Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hammond SA, Tan M, Qi J, Wong P, Merghoub T, Wolchok J, Hacohen N, Janik JE, Mkrtichyan M, Gupta S, Khleif SN. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 09; 20(9):1231-1243. PMID: 31358999.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  22. McKinley SK, Boland GM. The Patient Speaks: Importance of Patient Perspectives in Clinical Decision-Making. Ann Surg Oncol. 2019 Sep; 26(9):2665-2666. PMID: 31250344.
    Citations:    Fields:    Translation:Humans
  23. Chow MT, Ozga AJ, Servis RL, Frederick DT, Lo JA, Fisher DE, Freeman GJ, Boland GM, Luster AD. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. Immunity. 2019 06 18; 50(6):1498-1512.e5. PMID: 31097342.
    Citations: 35     Fields:    Translation:HumansAnimalsCells
  24. Hennessy ML, Bommareddy PK, Boland G, Kaufman HL. Oncolytic Immunotherapy. Surg Oncol Clin N Am. 2019 07; 28(3):419-430. PMID: 31079797.
    Citations:    Fields:    Translation:HumansAnimalsCells
  25. Chat V, Ferguson R, Simpson D, Kazlow E, Lax R, Moran U, Pavlick A, Frederick D, Boland G, Sullivan R, Ribas A, Flaherty K, Osman I, Weber J, Kirchhoff T. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer Immunol Immunother. 2019 Jun; 68(6):897-905. PMID: 30863922.
    Citations: 5     Fields:    Translation:HumansCells
  26. Sahu AD, S Lee J, Wang Z, Zhang G, Iglesias-Bartolome R, Tian T, Wei Z, Miao B, Nair NU, Ponomarova O, Friedman AA, Amzallag A, Moll T, Kasumova G, Greninger P, Egan RK, Damon LJ, Frederick DT, Jerby-Arnon L, Wagner A, Cheng K, Park SG, Robinson W, Gardner K, Boland G, Hannenhalli S, Herlyn M, Benes C, Flaherty K, Luo J, Gutkind JS, Ruppin E. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Mol Syst Biol. 2019 03 11; 15(3):e8323. PMID: 30858180.
    Citations:    Fields:    Translation:Humans
  27. Ludwig LS, Lareau CA, Ulirsch JC, Christian E, Muus C, Li LH, Pelka K, Ge W, Oren Y, Brack A, Law T, Rodman C, Chen JH, Boland GM, Hacohen N, Rozenblatt-Rosen O, Aryee MJ, Buenrostro JD, Regev A, Sankaran VG. Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics. Cell. 2019 03 07; 176(6):1325-1339.e22. PMID: 30827679.
    Citations: 23     Fields:    Translation:HumansCells
  28. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2019 Jan 10; 176(1-2):404. PMID: 30633907.
    Citations: 9     Fields:    
  29. Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2019 01; 565(7738):E4. PMID: 30532003.
    Citations: 1     Fields:    
  30. Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Chu CT, Liu S, Xu X, Krepler C, Xiao M, Xu W, Wei Z, Frederick DT, Boland G, Mitchell TC, Karakousis GC, Schuchter LM, Flaherty KT, Zhang G, Herlyn M, Koumenis C, Amaravadi RK. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer Discov. 2019 03; 9(3):396-415. PMID: 30563872.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  31. Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018 Dec; 24(12):1942. PMID: 30333558.
    Citations: 4     Fields:    
  32. Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24. PMID: 30388455.
    Citations: 77     Fields:    Translation:HumansAnimalsCells
  33. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018 11 01; 175(4):998-1013.e20. PMID: 30388456.
    Citations: 88     Fields:    Translation:HumansAnimalsCells
  34. Larimer BM, Bloch E, Nesti S, Austin EE, Wehrenberg-Klee E, Boland G, Mahmood U. The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clin Cancer Res. 2019 02 15; 25(4):1196-1205. PMID: 30327313.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  35. Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018 10; 24(10):1545-1549. PMID: 30127394.
    Citations: 30     Fields:    Translation:HumansCells
  36. Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC. Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell. 2018 08 09; 174(4):843-855.e19. PMID: 30017245.
    Citations: 41     Fields:    Translation:HumansAnimalsCells
  37. Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med. 2018 05; 10(5). PMID: 29650805.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  38. Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford P, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland GM, Wei Z, Nathanson K, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. 2018 10 01; 24(19):4771-4784. PMID: 29563139.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  39. Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, Liberti MV, Magpusao AN, Stein EM, Tingley JP, Frederick DT, Boland GM, Flaherty KT, McCall SJ, Krepler C, Sproesser K, Herlyn M, Adams DJ, Locasale JW, Cichowski K, Mukherjee S, Wood KC. Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. Cell Rep. 2017 Dec 05; 21(10):2796-2812. PMID: 29212027.
    Citations: 9     Fields:    Translation:HumansCells
  40. Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H. A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. Cancer Immunol Res. 2018 01; 6(1):79-86. PMID: 29208646.
    Citations: 13     Fields:    Translation:Humans
  41. Kasumova GG, Haynes AB, Boland GM. Lymphatic versus Hematogenous Melanoma Metastases: Support for Biological Heterogeneity without Clear Clinical Application. J Invest Dermatol. 2017 12; 137(12):2466-2468. PMID: 29169461.
    Citations:    Fields:    Translation:Humans
  42. Rand AJ, Flejter WL, Dowling CA, Brooke LM, Boland GM, Kroshinsky D, Rosenblum IR, Hernandez-Perez M, Reimann JDR. Atypical ALK-positive Spitz tumors with 9p21 homozygous deletion: Report of two cases and review of the literature. J Cutan Pathol. 2018 Feb; 45(2):136-140. PMID: 29028122.
    Citations:    Fields:    Translation:Humans
  43. Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018 02; 8(2):216-233. PMID: 29101163.
    Citations: 50     Fields:    Translation:HumansAnimalsCells
  44. Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215. PMID: 29101162.
    Citations: 40     Fields:    Translation:HumansAnimalsCells
  45. Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, Frederick DT, Hazar-Rethinam M, Nadres BA, Van Seventer EE, Shukla SA, Yizhak K, Ray JP, Rosebrock D, Livitz D, Adalsteinsson V, Getz G, Duncan LM, Li B, Corcoran RB, Lawrence DP, Stemmer-Rachamimov A, Boland GM, Landau DA, Flaherty KT, Sullivan RJ, Hacohen N. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017 10 26; 8(1):1136. PMID: 29070816.
    Citations: 89     Fields:    Translation:HumansAnimals
  46. Lu H, Liu S, Zhang G, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017 10 05; 550(7674):133-136. PMID: 28953887.
    Citations: 37     Fields:    Translation:HumansAnimalsCells
  47. Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, Boland G, Mahmood U. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Res. 2017 05 01; 77(9):2318-2327. PMID: 28461564.
    Citations: 38     Fields:    Translation:HumansAnimalsCells
  48. Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, Chiorino G, Pellegrini M, Herlyn M, Osman I, Poliseno L. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 2017 Apr 11; 8(15):25395-25417. PMID: 28445987.
    Citations: 15     Fields:    Translation:HumansCells
  49. Raigani S, Cohen S, Boland GM. The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. Curr Oncol Rep. 2017 Mar; 19(3):17. PMID: 28251494.
    Citations: 5     Fields:    Translation:Humans
  50. Khosravi H, Akabane AL, Alloo A, Nazarian RM, Boland GM. Metastatic melanoma with spontaneous complete regression of a thick primary lesion. JAAD Case Rep. 2016 Nov; 2(6):439-441. PMID: 27981212.
    Citations: 6     
  51. Roland CL, Boland GM, Demicco EG, Lusby K, Ingram D, May CD, Kivlin CM, Watson K, Al Sannaa GA, Wang WL, Ravi V, Pollock RE, Lev D, Cormier JN, Hunt KK, Feig BW, Lazar AJ, Torres KE. Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surg. 2016 Apr; 151(4):347-54. PMID: 26629783.
    Citations: 4     Fields:    Translation:Humans
  52. Boland GM, Gershenwald JE. Principles of Melanoma Staging. Cancer Treat Res. 2016; 167:131-48. PMID: 26601861.
    Citations: 7     Fields:    Translation:Humans
  53. Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110. PMID: 26015395.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  54. DePeralta DK, Boland GM. Melanoma: Advances in Targeted Therapy and Molecular Markers. Ann Surg Oncol. 2015 Oct; 22(11):3451-8. PMID: 26224403.
    Citations: 6     Fields:    Translation:HumansCells
  55. Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, Chin L. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70. PMID: 25705882.
    Citations: 43     Fields:    Translation:HumansAnimals
  56. Demicco EG, Boland GM, Brewer Savannah KJ, Lusby K, Young ED, Ingram D, Watson KL, Bailey M, Guo X, Hornick JL, van de Rijn M, Wang WL, Torres KE, Lev D, Lazar AJ. Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value. Histopathology. 2015 Apr; 66(5):627-38. PMID: 24889065.
    Citations: 8     Fields:    Translation:Humans
  57. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515. PMID: 25148578.
    Citations: 39     Fields:    Translation:Humans
  58. Boland GM, Meric-Bernstam F. The role of surgeons in building a personalized medicine program. J Surg Oncol. 2015 Jan; 111(1):3-8. PMID: 24964977.
    Citations:    Fields:    Translation:Humans
  59. Boland G. Reverberation. Pharos Alpha Omega Alpha Honor Med Soc. 2013; 76(3):22-6. PMID: 23957074.
    Citations:    Fields:    Translation:Humans
  60. Boland GM, Chang GJ, Haynes AB, Chiang YJ, Chagpar R, Xing Y, Hu CY, Feig BW, You YN, Cormier JN. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer. 2013 Apr 15; 119(8):1593-601. PMID: 23280510.
    Citations: 51     Fields:    Translation:Humans
  61. Santamaria-Barria JA, Boland GM, Yeap BY, Nardi V, Dias-Santagata D, Cusack JC. Merkel cell carcinoma: 30-year experience from a single institution. Ann Surg Oncol. 2013 Apr; 20(4):1365-73. PMID: 23208132.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  62. Chiang YS, Boland GM, Xing Y, Massarweh NN, Chang GJ, You YN, Feig BW, Cormier JN. Socioeconomic and clinical factors associated with delayed initiation of adjuvant chemotherapy for stage III colon cancer. J Clin Oncol. 2012 Dec; 30(34_suppl):173. PMID: 28147180.
    Citations:    
  63. Boland GM, Gershenwald JE. Sentinel lymph node biopsy in melanoma. Cancer J. 2012 Mar-Apr; 18(2):185-91. PMID: 22453020.
    Citations: 8     Fields:    Translation:Humans
  64. Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012 Mar 01; 18(5):1227-36. PMID: 22261808.
    Citations: 32     Fields:    Translation:HumansCells
  65. Baksh D, Boland GM, Tuan RS. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J Cell Biochem. 2007 Aug 01; 101(5):1109-24. PMID: 17546602.
    Citations: 61     Fields:    Translation:HumansCells
  66. Boland GM, Weigel RJ. Formation and prevention of postoperative abdominal adhesions. J Surg Res. 2006 May; 132(1):3-12. PMID: 16457846.
    Citations: 28     Fields:    Translation:Humans
  67. Boland GM, Perkins G, Hall DJ, Tuan RS. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem. 2004 Dec 15; 93(6):1210-30. PMID: 15486964.
    Citations: 166     Fields:    Translation:HumansCells
  68. Kampov-Polevoy AB, Eick C, Boland G, Khalitov E, Crews FT. Sweet liking, novelty seeking, and gender predict alcoholic status. Alcohol Clin Exp Res. 2004 Sep; 28(9):1291-8. PMID: 15365298.
    Citations: 29     Fields:    Translation:Humans
  69. Kampov-Polevoy AB, Ziedonis D, Steinberg ML, Pinsky I, Krejci J, Eick C, Boland G, Khalitov E, Crews FT. Association between sweet preference and paternal history of alcoholism in psychiatric and substance abuse patients. Alcohol Clin Exp Res. 2003 Dec; 27(12):1929-36. PMID: 14691380.
    Citations: 20     Fields:    Translation:Humans
  70. Tuan RS, Boland G, Tuli R. Adult mesenchymal stem cells and cell-based tissue engineering. Arthritis Res Ther. 2003; 5(1):32-45. PMID: 12716446.
    Citations: 159     Fields:    Translation:HumansCells
  71. Fischer L, Boland G, Tuan RS. Wnt-3A enhances bone morphogenetic protein-2-mediated chondrogenesis of murine C3H10T1/2 mesenchymal cells. J Biol Chem. 2002 Aug 23; 277(34):30870-8. PMID: 12077113.
    Citations: 33     Fields:    Translation:AnimalsCells
  72. Fischer L, Boland G, Tuan RS. Wnt signaling during BMP-2 stimulation of mesenchymal chondrogenesis. J Cell Biochem. 2002; 84(4):816-31. PMID: 11835406.
    Citations: 23     Fields:    Translation:AnimalsCells
  73. Mehta A, Dreyer K, Boland G, Frank M. Do picture archiving and communication systems improve report turnaround times? J Digit Imaging. 2000 May; 13(2 Suppl 1):105-7. PMID: 10847375.
    Citations: 12     Fields:    Translation:Humans
  74. Thrall JH, Boland G. Telemedicine in practice. Semin Nucl Med. 1998 Apr; 28(2):145-57. PMID: 9579416.
    Citations: 10     Fields:    Translation:Humans
  75. Boland G, Lee MJ, Mueller PR. Acute cholecystitis in the intensive care unit. New Horiz. 1993 May; 1(2):246-60. PMID: 7922407.
    Citations: 1     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Boland's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (335)
Explore
_
Co-Authors (109)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.